Close Menu

NEW YORK (GenomeWeb) – The Illumina-sponsored Actionable Genome Consortium reported this week that cell-free DNA-based tumor genotyping for non-small cell lung cancer patients is concordant with tissue tumor-based genotyping most of the time and could be particularly useful in cases where acquiring a tissue biopsy is not feasible.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.